Evinacumab - Regeneron Pharmaceuticals

Drug Profile

Evinacumab - Regeneron Pharmaceuticals

Alternative Names: REGN-1500

Latest Information Update: 17 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Regeneron Pharmaceuticals; Sanofi
  • Developer Regeneron Pharmaceuticals
  • Class Antihyperlipidaemics; Monoclonal antibodies
  • Mechanism of Action ANGPTL3 protein inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypercholesterolaemia; Hyperlipoproteinaemia type IIa; Hypertriglyceridaemia

Most Recent Events

  • 23 Jul 2018 Regeneron Pharmaceuticals completes a phase IIa trial for Hyperlipoproteinaemia type IIa in USA, Canada and Netherlands (NCT02265952)
  • 14 Jun 2018 Regeneron Pharmaceuticals completes a phase I trial in Healthy volunteers in USA (NCT03146416)
  • 03 May 2018 Regeneron Pharmaceuticals plans a phase II trial for Hypertriglyceridaemia, in April 2018 (NCT03452228)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top